Sinonasal Squamous Cell Carcinoma in the Netherlands: A Population-Based Study of 568 Cases Diagnosed in 2008-2021.

IF 2.3 3区医学 Q1 OTORHINOLARYNGOLOGY

Head and Neck-Journal for the Sciences and Specialties of the Head and Neck Pub Date : 2024-10-16 DOI:10.1002/hed.27961

Lise J van de Velde, W F Julius Scheurleer, W Weibel Braunius, Caroline M Speksnijder, Mischa de Ridder, Lot A Devriese, Remco de Bree, Gerben E Breimer, Johannes A Rijken, Boukje A C van Dijk

{"title":"Sinonasal Squamous Cell Carcinoma in the Netherlands: A Population-Based Study of 568 Cases Diagnosed in 2008-2021.","authors":"Lise J van de Velde, W F Julius Scheurleer, W Weibel Braunius, Caroline M Speksnijder, Mischa de Ridder, Lot A Devriese, Remco de Bree, Gerben E Breimer, Johannes A Rijken, Boukje A C van Dijk","doi":"10.1002/hed.27961","DOIUrl":null,"url":null,"abstract":"Background: Sinonasal squamous cell carcinoma is known for its rarity and poor prognosis. This study aims to investigate the trends in the incidence of sinonasal squamous cell carcinoma in the Netherlands and to analyze patient characteristics and treatment practices in order to assess their relation with patient outcomes.Methods: In this prospectively designed population-based cohort study, all patients diagnosed with sinonasal squamous cell carcinoma between 2008 and 2021 in the Netherlands were included. Patients with a squamous cell carcinoma of the nasal vestibule were excluded, leading to a definitive study population of 568 cases.Results: The annual incidence rate for the overall population displayed a slight upward trend over the inclusion period with an annual percentage change of 1.6%. The 5-year overall, disease-free, and relative survival were 43.0%, 52.0%, and 47.2%, respectively. Relative survival decreased marginally over the course of the inclusion period.Conclusion: Sinonasal squamous cell carcinoma is rare with approximately stable incidence rates. There is a limited, non-statistically significant, decrease in survival between 2008 and 2021. Therefore, there is a clear need for innovative treatment approaches to improve outcomes for patients with sinonasal squamous cell carcinoma.","PeriodicalId":55072,"journal":{"name":"Head and Neck-Journal for the Sciences and Specialties of the Head and Neck","volume":null,"pages":null},"PeriodicalIF":2.3000,"publicationDate":"2024-10-16","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Head and Neck-Journal for the Sciences and Specialties of the Head and Neck","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1002/hed.27961","RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q1","JCRName":"OTORHINOLARYNGOLOGY","Score":null,"Total":0}

引用次数: 0

Abstract

Background: Sinonasal squamous cell carcinoma is known for its rarity and poor prognosis. This study aims to investigate the trends in the incidence of sinonasal squamous cell carcinoma in the Netherlands and to analyze patient characteristics and treatment practices in order to assess their relation with patient outcomes.

Methods: In this prospectively designed population-based cohort study, all patients diagnosed with sinonasal squamous cell carcinoma between 2008 and 2021 in the Netherlands were included. Patients with a squamous cell carcinoma of the nasal vestibule were excluded, leading to a definitive study population of 568 cases.

Results: The annual incidence rate for the overall population displayed a slight upward trend over the inclusion period with an annual percentage change of 1.6%. The 5-year overall, disease-free, and relative survival were 43.0%, 52.0%, and 47.2%, respectively. Relative survival decreased marginally over the course of the inclusion period.

Conclusion: Sinonasal squamous cell carcinoma is rare with approximately stable incidence rates. There is a limited, non-statistically significant, decrease in survival between 2008 and 2021. Therefore, there is a clear need for innovative treatment approaches to improve outcomes for patients with sinonasal squamous cell carcinoma.

查看原文本刊更多论文

荷兰的鼻窦鳞状细胞癌：对 2008-2021 年确诊的 568 例病例进行的基于人口的研究。

背景介绍鼻窦鳞状细胞癌以罕见和预后不良而闻名。本研究旨在调查荷兰鼻窦鳞状细胞癌的发病趋势，分析患者特征和治疗方法，以评估它们与患者预后的关系：在这项前瞻性设计的人群队列研究中，纳入了2008年至2021年间荷兰所有确诊为鼻窦鳞状细胞癌的患者。结果：荷兰鼻窦鳞状细胞癌患者的年发病率为1.5%，而鼻前庭鳞状细胞癌患者的年发病率为1.5%：在纳入期间，总体人群的年发病率呈轻微上升趋势，年百分比变化为 1.6%。5年总生存率、无病生存率和相对生存率分别为43.0%、52.0%和47.2%。相对生存率在纳入期间略有下降：结论：鼻窦鳞状细胞癌非常罕见，发病率基本稳定。结论：鼻窦鳞状细胞癌较为罕见，发病率基本稳定，2008年至2021年期间的生存率下降有限，但无统计学意义。因此，显然需要创新的治疗方法来改善鼻窦鳞状细胞癌患者的预后。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

Head and Neck-Journal for the Sciences and Specialties of the Head and Neck 医学-耳鼻喉科学

CiteScore

7.00

自引率

6.90%

发文量

278

审稿时长

1.6 months

期刊介绍： Head & Neck is an international multidisciplinary publication of original contributions concerning the diagnosis and management of diseases of the head and neck. This area involves the overlapping interests and expertise of several surgical and medical specialties, including general surgery, neurosurgery, otolaryngology, plastic surgery, oral surgery, dermatology, ophthalmology, pathology, radiotherapy, medical oncology, and the corresponding basic sciences.